Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Linda van Bijsterveldt

BSc, MRes

DPhil Student

I am looking into the role of the miR-106b/25 cluster in regulating breast cancer pathogenesis. We have shown that over-expression of this miRNA alters the cell cycle profile of triple-negative breast cancer cell lines and are looking to target this with checkpoint kinase inhibitors, based on a concept called synthetic lethality.

graduated from Leiden University (2016) with a BSc in Bio-Pharmaceutical Sciences. I then obtained a MSc by Research in Oncology (2017) from the University of Oxford (Chromosome Integrity Group), where I identified suppressors of the synthetic lethality resulting from loss of SETD2 and WEE1.